ノイガストロクスのNG101薬は,フェーズ2の試験で2割まで、スマグリトイドユーザーの吐き気と嘔吐を軽減した. Neurogastrx's NG101 drug reduced nausea and vomiting in semaglutide users by up to 70% in a Phase 2 trial.

肥満と糖尿病の治療に用いられる一般的なGLP-1薬であるセマグルチドを服用した患者で,口服薬NG101のフェーズ2試験の結果が陽性であることが報告されました. Neurogastrx reported positive Phase 2 trial results for NG101, an oral drug that significantly reduced nausea and vomiting in people taking semaglutide, a common GLP-1 medication for obesity and diabetes. 90人の成人を対象とした研究では,NG101は,悪心症を40%減らし,嘔吐症を67%減らし,症状の重症度を70%減らし,副作用も少なくなった. In a study of 90 adults, NG101 cut nausea by 40%, vomiting by 67%, and reduced symptom severity by 70% compared to placebo, with fewer side effects. この薬は脳内の食欲制御センターに影響を及ぼさずに 吐き気を狙い 患者さんを有効な治療に長く留めるのに役立ちます The drug, which targets nausea without affecting the brain’s appetite control center, may help patients stay on effective treatments longer. 成果はObesityWeek 2025で発表され,開発が進んでいくにつれて,同社は新しいCEOを任命した. Results were presented at ObesityWeek 2025, and the company also named a new CEO as it advances development.